# US 6,727,249 B2 · Azabicyclic ether derivatives and their use as therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,249 B2
- Document ID: US6727249B2
- Status: Granted
- Kind: B2
- Application number: 10/113,117
- Filed: 2002-04-01
- Published: 2002-12-19
- Granted: 2004-04-27
- Earliest claimed: 2001-04-10
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Neil Roy Curtis; Ian Thomas Huscroft; Janusz Jozef Kulagowski; Piotr Antoni Raubo
- Web page: https://patentgrep.com/patent/US6727249B2

## CPC

- C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates compounds of the formula (I): wherein X represents hydrogen, C1-4alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO2(C1-2alkyl); Z is —CR9R10CH2— or —CH2CR9R10—; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.

## Claims

### Claim 1

A compound of the formula (I):
wherein
X represents hydrogen, C1-4alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO2(C1-2alkyl);
Z is —CR9R10CH2— or —CH2CR9R10—;
R1 is hydrogen, halogen, C1-6alkyl, C1-6alkoxy, fluoroC1-6alkyl, fluoroC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, NO2, CN, SRa, SORa, SO2Ra, CO2Ra, CONRaRb, C2-6alkenyl, C2-6alkynyl or C1-4alkyl substituted by C1-4alkoxy, wherein Ra and Rb each independently represent hydrogen or C1-4alkyl;
R2 is hydrogen, halogen, C1-6alkyl, fluoroC1-6alkyl or C1-6alkoxy substituted by C1-4alkoxy;
R3 is hydrogen, halogen or fluoroC1-6alkyl;
R4 represents hydrogen, halogen, C1-6alkyl, C1-6alkoxy, CF3, OCF3, NO2, CN, SRa, SORa, SO2Ra, CO2Ra, CONRaRb, C2-6alkenyl, C2-6alkynyl or C1-4alkyl substituted by C1-4alkoxy, where Ra and Rb are as previously defined;
R5 represents hydrogen, halogen, C1-6alkyl, CF3 or C1-6alkoxy substituted by C1-4alkoxy;
R6 represents hydrogen, hydroxy, CORa, CO2Ra, COCONRaRb, COCO2Ra, C1-6alkyl, C2-6alkenyl, or C1-6alkyl substituted by a group selected from CO2Ra, CONRaRb, hydroxy, CN, CORa, NRaRb, C(NOH)NRaRb, CONHphenyl(C1-4alkyl), COCO2Ra, CONHNRaRb, C(S)NRaRb, CONRaC1-6alkylR14, CONR11C2-6alkenyl, CONR11C2-6alkynyl, COCONRaRb, CONRaC(NRb)NRaRb, CONRaheteroaryl, (wherein heteroaryl is selected from the group consisting of pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indole, benzofuran, benzthiophene, benzimidazole, benzoxazole, benzthiazole and quinolinyl), and phenyl, optionally substituted by one, two or three substituents selected from C1-6alkyl, C1-6alkoxy, halogen and trifluoromethyl;
or R6 represents a group of the formula —CH2C≡CCH2NR7R8 where R7 and R8 are as defined below;
or R6 represents C1-6alkyl, optionally substituted by oxo, substituted by heterocyclic ring which is selected from the group consisting of 1,3-imidazol-4-yl, 1,2,4-triazol-3-yl, 1,2,3-triazol-4-yl, 2-oxo-1,3-imidazol-4-yl and 3-oxo-1,2,4-triazol-5-yl, which is unsubstituted or substituted by ═O or ═S or a group of the formula —Y—NR7R8 where
Y is C1-6alkylene or C3-6cycloalkyl;
R7 represents hydrogen or C1-4alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or C2-4alkyl substituted by C1-4alkoxy or hydroxyl;
R8 represents hydrogen or C1-6alkyl, C1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, phenyl or C1-4alkyl substituted by a group selected from C1-4alkoxy, hydroxyl, CO2Ra, NRaRb, phenyl, phenyloxy, pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indole, benzofuran, benzthiophene, benzimidazole, benzoxazole, benzthiazole, quinolinyl, azetidinyl, pyrrolidino, piperidino, piperazino, morpholino, or thiomorpholino;
or R7, R8 and the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, morpholino, or piperazinyl which is unsubstituted or substituted by one or two groups selected from methyl, hydroxy, CO2(C1-2alkyl), phenyl, benzyl or C1-4alkoxy optionally substituted by a C1-4alkoxy or hydroxyl group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH or NRc moiety where Rc is C1-4alkyl, hydroxyC1-4alkyl, C1-4alkoxyC1-4alkyl, phenyl or benzyl;
or R7, R8 and the nitrogen atom to which they are attached form 5-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.2.1]heptyl, 6-azabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.2]octyl, 6-azabicyclo[3.2.2]nonyl, 6-azabicyclol[3.3.1]nonyl, 6-azabicyclo[3.2.2]decyl, 7-azabicyclo[4.3.1]decyl, 7-azabicyclol[4.4.1]undecyl or 8-azabicyclo[5.4.1]dodecyl;
or Y, R7 and the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl or morpholinyl ring;
R9 represents hydrogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, fluoroC1-6alkyl, C1-6alkoxy, fluoroC1-6alkoxy, hydroxyC1-6alkyl, C1-6alkoxyC1-4alkyl, C1-6alkoxyC1-4alkoxy, fluoroC1-6alkoxyC1-4alkyl, C2-6alkenyloxy, C2-6alkynyloxy, C3-7cycloalkoxy, C3-7cycloalkylC1-4alkoxy, phenyl, phenyl(CH2), phenyloxy, phenyl(CH2)oxy, cyano, halogen, NR7R8, CH2NR7R8, SR12, SOR12, SO2R12, OSO2R12, NRaCOR12, CH(OH)R12, COR12, CO2R12, CONR7R8, CONHNH2, CH2OR13, pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indole, benzofuran, benzthiophene, benzimidazole, benzoxazole, benzthiazole, quinolinyl, pyrrolylC1-4alkyl, furanylC1-4alkyl, thienylC1-4alkyl, pyridylC1-4alkyl, pyrazolylC1-4alkyl, imidazolylC1-4alkyl, oxazolyC1-4alkyll, isoxazolylC1-4alkyl, thiazolylC1-4alkyl, isothiazolylC1-4alkyl, pyrazinylC1-4alkyl, pyrimidinylC1-4alkyl, pyridazinylC1-4alkyl, triazolylC1-4alkyl, oxadiazolylC1-4alkyl, thiadiazolylC1-4alkyl, triazinylC1-4alkyl, tetrazolylC1-4alkyl, indoleC1-4alkyl, benzofuranC1-4alkyl, benzthiopheneC1-4alkyl, benzimidazoleC1-4alkyl, benzoxazoleC1-4alkyl, benzthiazoleC1-4alkyl and quinolinylC1-4alkyl;
R10 represents hydrogen, halogen or hydroxy;
R11 represents hydrogen or C1-6alkyl;
R12 represents hydrogen, C1-6alkyl, C1-6alkoxy, fluoroC1-6alkyl or phenyl optionally substituted by one, two or three substituents selected from C1-6alkyl, C1-6alkoxy, halogen or trifluoromethyl;
R13 represents C1-4alkyl substituted by a group selected from hydroxy, CORa, CO2Ra, CONRaRb, pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indole, benzofuran, benzthiophene, benzimidazole, benzoxazole, benzthiazole, quinolinyl;
R14 represents ORa, CONRaRb, pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indole, benzofuran, benzthiophene, benzimidazole, benzoxazole, benzthiazole, or quinolinyl;
or a pharmaceutically acceptable salt or N-oxide thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R1 is hydrogen, C1-4alkyl, C1-4alkoxy, halogen or CF3.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R2 is hydrogen, C1-4alkyl, C1-4alkoxy, halogen or CF3.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R3 is hydrogen, fluorine, chlorine or CF3.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R4 is hydrogen or fluorine.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R5 is hydrogen.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R6 is hydrogen or C1-6alkyl, or a C1-3alkyl group substituted by 1,3-imidazol-4-yl, 1,2,4-triazol-3-yl, 1,2,3-triazol-4-yl, 2-oxo-1,3-imidazol-4-yl or 3-oxo-1,2,4-triazol-5-yl.

### Claim 8 (depends on 1)

The compound of claim 1 wherein Z is —CR9R10CH2—.

### Claim 9 (depends on 1)

The compound of claim 1 wherein R9 is hydrogen, hydroxy, oxo, C1-6alkoxy, C1-6alkoxyC1-4alkyl, hydroxyC1-4alkyl, cyano, NR7R8, CH2NR7R8, SO2Rd, CH(OH)R12, COR12, CO2R12, CONR7R8, phenyl, pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indole, benzofuran, benzthiophene, benzimidazole, benzoxazole, benzthiazole, quinolinyl, pyrrolylC1-4alkyl, furanylC1-4alkyl, thienylC1-4alkyl, pyridylC1-4alkyl, pyrazolylC1-4alkyl, imidazolylC1-4alkyl, oxazolyC1-4alkyll, isoxazolylC1-4alkyl, thiazolylC1-4alkyl, isothiazolylC1-4alkyl, pyrazinylC1-4alkyl, pyrimidinylC1-4alkyl, pyridazinylC1-4alkyl, triazolylC1-4alkyl, oxadiazolylC1-4alkyl, thiadiazolylC1-4alkyl, triazinylC1-4alkyl, tetrazolylC1-4alkyl, indoleC1-4alkyl, benzofuranC1-4alkyl, benzthiopheneC1-4alkyl, benzimidazoleC1-4alkyl, benzoxazoleC1-4alkyl, benzthiazoleC1-4alkyl and quinolinylC1-4alkyl, or CH2OR13, where said phenyl is optionally substituted by one or two substituents selected from C1-4alkyl, C1-4alkoxy, halogen or trifluoromethyl.

### Claim 10 (depends on 1)

The compound of claim 1 wherein R10 is hydrogen, fluorine or hydroxy.

### Claim 11 (depends on 1)

The compound of claim 1 wherein X is hydrogen, methyl or hydroxymethyl.

### Claim 12 (depends on 1)

The compound of claim 1 of the formula (Ia):
wherein Z is —CR9R10CH2—;
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1 wherein the stereochemistry of the 1-, 2-, and 5-positions is as shown in formula (Ib):

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable carrier or excipient.

### Claim 15 (depends on 1)

A method for the treatment of physiological disorders associated with an excess of tachykinins, which method comprises administration to a patient in need thereof of a tachykinin, reducing amount of the compound of claim 1.

### Claim 16 (depends on 15)

The method according to claim 15 for the treatment, migraine, emesis, postherpetic neuralgia, depression or anxiety.
